Nexalin Technology (NASDAQ:NXL – Get Free Report) and ENDRA Life Sciences (NASDAQ:NDRA – Get Free Report) are both small-cap business services companies, but which is the superior stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, risk, dividends, institutional ownership and profitability.
Institutional and Insider Ownership
0.7% of Nexalin Technology shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 24.0% of Nexalin Technology shares are owned by insiders. Comparatively, 0.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Profitability
This table compares Nexalin Technology and ENDRA Life Sciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Nexalin Technology | -3,407.98% | -187.59% | -167.21% |
| ENDRA Life Sciences | N/A | -127.39% | -103.77% |
Earnings and Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Nexalin Technology | $110,000.00 | 503.88 | -$4.65 million | ($0.64) | -6.73 |
| ENDRA Life Sciences | N/A | N/A | -$10.06 million | ($901.15) | -0.01 |
Nexalin Technology has higher revenue and earnings than ENDRA Life Sciences. Nexalin Technology is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Nexalin Technology has a beta of 3.78, suggesting that its share price is 278% more volatile than the S&P 500. Comparatively, ENDRA Life Sciences has a beta of 0.67, suggesting that its share price is 33% less volatile than the S&P 500.
Analyst Ratings
This is a summary of recent ratings for Nexalin Technology and ENDRA Life Sciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Nexalin Technology | 0 | 0 | 1 | 0 | 3.00 |
| ENDRA Life Sciences | 0 | 0 | 1 | 0 | 3.00 |
Nexalin Technology presently has a consensus price target of $3.00, suggesting a potential downside of 30.39%. ENDRA Life Sciences has a consensus price target of $700,000.00, suggesting a potential upside of 13,565,791.47%. Given ENDRA Life Sciences’ higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Nexalin Technology.
Summary
ENDRA Life Sciences beats Nexalin Technology on 6 of the 11 factors compared between the two stocks.
About Nexalin Technology
Nexalin Technology, Inc., a medical device company, designs and develops neurostimulation products for the treatment of mental health in the United States and China. The company designs and develops Generation 2 and Generation 3, that is in clinical trials for the treatment of substance abuse issues related to opiate, cocaine, alcohol abuse, alzheimer's disease, and dementia. It also licenses and sells Nexalin Device, a non-invasive and undetectable to the human body that can provide relief to its afflicted with mental health issues. The company is based in Houston, Texas.
About ENDRA Life Sciences
ENDRA Life Sciences Inc. develops technologies to improve the capabilities of clinical diagnostic ultrasound. The company is developing thermo-acoustic enhanced ultrasound technology that uses radio frequency pulses to generate ultrasonic waves in tissue to create high-contrast images for use in the treatment of nonalcoholic fatty liver disease, as well as in tissue composition, temperature monitoring, vascular imaging, and tissue perfusion. It has a collaborative research agreement with General Electric Company. ENDRA Life Sciences Inc. was incorporated in 2007 and is based in Ann Arbor, Michigan.
Receive News & Ratings for Nexalin Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexalin Technology and related companies with MarketBeat.com's FREE daily email newsletter.
